Search companies or stocks...
Kiniksa Pharmaceuticals, Ltd. (KNSA) intrinsic value snapshot: our valuation models currently suggest the stock is overvalued, with an estimated 167.7% downside relative to fair value at a market price of $63.44. The dollar intrinsic value (fair value) for Kiniksa Pharmaceuticals, Ltd. is derived from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for investors comparing market price to modeled fair value.
Current Price: $63.44
Valuation: Overvalued
Confidence: 9.5/10
How we calculate fair value: We combine DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models to estimate intrinsic value. This figure is for information only - not investment advice - and assumptions may not reflect actual market conditions. We encourage doing your own research or speaking with a financial advisor before making investment decisions.
Search our company database (same as the site header), pick a match, or type a ticker to open its intrinsic value analysis.
Based on our intrinsic value models, Kiniksa Pharmaceuticals, Ltd. (KNSA) currently looks overvalued with an estimated 167.71% downside relative to fair value at $63.44. Sign in to Tickerplace Pro to view the full dollar fair value estimate and margin of safety.
Kiniksa Pharmaceuticals, Ltd. (KNSA) fair value vs market price: our valuation models suggest overvalued positioning with an estimated 167.7% downside relative to intrinsic value at a market price of $63.44. The dollar fair value for Kiniksa Pharmaceuticals, Ltd. is calculated from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for a full market-price-to-fair-value breakdown and margin of safety.
Our models calculate the intrinsic value of Kiniksa Pharmaceuticals, Ltd. (KNSA) using DCF, P/E Multiple, and P/S Multiple approaches based on projected cash flows, growth rate, and discount rate. Sign in to Tickerplace Pro to view the full dollar estimate.
Based on our 2026 valuation models, KNSA appears overvalued at its current price of $63.44. Our model suggests the stock may be overvalued by 167.7%.
Tickerplace calculates KNSA's intrinsic value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We project future cash flows, apply a discount rate that reflects investment risk, and compare the resulting fair value estimate to the current market price.
Peers for KNSA: open their intrinsic value pages.
